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Transcription of the gene encoding melanoma- 
associated antigen gplOO in tissues and cell lines other 
than those of the melanocytic lineage
N Brouwenstijn1, EH Slager1, ABH Bakker2, MWJ Schreurs2, CW Van der Spek1, GJ Adema2, PI Schrier1 
and CG Figdor2
'Department of Clinical Oncology, University Hospital Leiden, PO Box 9600, 2300 RC Leiden; and ^Department of Tumor Immunology, University Hospital 
Nijmegen, Philips van Leydenlaan 25, 6525 EX Nijmegen, The Netherlands
Summary The expression of the gp100 antigen is generally thought to be confined to cells of the melanocytic lineage, which makes the 
protein a suitable melanoma-specific marker. Strikingly, after screening a panel of normal tissues, tumour samples and cell lines of non- 
melanocytic origin, we found transcripts encoding gp100 in virtually every tissue and cell line tested. In contrast, tyrosinase and MART- 
1/MelanA transcripts were detected only in cells of the melanocytic lineage. However, no gp100 protein could be detected by either Western 
blotting or cytotoxicity assays. Therefore, at the protein level, gp100 remains exclusive for cells of melanocytic origin despite its transcription 
in many cell types. The major implication of this finding is that screening of patient material for gp100 expression should preferrably be 
performed by antibody staining. Reverse transcriptase polymerase chain reaction (RT-PCR) can be employed, provided that it is performed in 
a tightly controlled, semiquantitative setting.
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The molecular cloning of tumour-associated antigens has provided 
new tools for the immunotherapy of cancer (reviewed in Van den 
Eynde and Brichard, 1995). Now it has become feasible to immu­
nize cancer patients against these antigens to stimulate specifically 
a cellular anti-tumour response (Marchand et al, 1995). To select 
patients eligible for immunotherapeulic protocols, the antigenic 
profiles of the patients' tumours must be characterized. This is 
usually achieved by reverse transcriptase polymerase chain reac­
tion (RT-PCR) using RNA obtained from tumour samples when 
available. An alternative source of tumour cells is whole blood, 
which often contains numerous circulating residual tumour cells 
(Brossait et al, 1995; Hoon et al, 1995). A suitable antigen to 
target in melanoma is gp 100 because it is thought to be specific for 
cells of melanocytic lineage and it is adequately expressed in 
melanoma cells. Expression in non-melanocytic cells, at least as 
measured by antibody reactivity et al, or
Northern analysis (Kawakami et al, 1994), is virtually absent. In a 
routine RT-PCR screening of a number of human tumour samples 
and normal tissues, we noticed to our surprise that gp 100 
transcripts were present in almost all materials tested, whereas 
the protein was not detectable.
MATERIALS AND METHODS
Tumour cell lines, samples and normal tissues
The renal cell carcinoma cell lines (RCC) LE-9I04-RCC, LE- 
9211-RCC and LE-9415-RCC and the melanoma cell line Mel 603 
were established in our laboratory. The RCC cell line SK-RC-7 
was kindly provided by Dr E Oosterwijk (Department of Urology, 
Nijmegen University, The Netherlands). The RCC cell lines MZ- 
1851-RCC and Camejo and melanoma cell lines MZ-2-mel and 
MZ-7.4-mel were generously provided by Dr B 
Gutenberg University, Mainz, Germany). The breast carcinoma
lines (BRCA) MCF-7 and SK-BR-3 were a gift from 
Dr R Kuypers (Department of Pathology, Leiden University, 
The Netherlands). The ovarian carcinoma cell lines (OVCA) COV 
434 and COV 413A were established in our laboratory (Van den 
Bcrg-Bakker et al, 1993). The melanoma cell line Mel 624 and 
TIL 1200 lymphocytes were kindly provided by Dr Y Kawakami 
(NCI. NIH, Bethesda, MD, USA). LE-8915-EBV and PS-EBV 
are EBV-transformed B-cell lines established in our laboratory. 
BLM is a melanoma cell line (Bakker et al, 1994). Normal tissues 
were obtained after death from a woman without cancer. Fresh 
retina was kindly provided by Dr M Jager (Department of 
Ophthalmology, Leiden University, The Netherlands).
Received 20 January 1997 
Revised 25 April 1997 
Accepted 12 May 1997
Correspondence to: PI Schrier, Department of Clinical Oncology, University 
Hospital Leiden, bldg. 1, K1, PO Box 9600, 2300 RC Leiden, The 
Netherlands
RNA isolation and cDNA synthesis
Total RNA was isolated by guanidine-thiocyanate (HSCN) extrac­
tion as described by Chomczynski and Sacchi (1987) or using 
RNAzolB (Tel-Test, Friendswood, TX, USA). Before cDNA
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Table 1 Absence of cytotoxicity of TIL 1200 towards gp100-positive RCC 
cell lines
HLA-A*0201 gp100 % specific lysis (+ W6/32)b
E:T ratio 30:1 10:1 3:1
Cell line"
BLM + — 2 2 0
(0) ( - 2 ) ( -1 )
Mel 624 + + 58 37 17
(14) (7) (0)
LE-9104-RCC p|» 2 0 0
(3) (1) ( - 1 )
LE-9415-RCC + + - 2 - 2 ~~ s
( -5 ) ( - 4 ) ( -  3)
MZ-1851-RCC ■*!* ■tji* 3 4 2
(2) ( - 1 ) (1)
Camejo + 0 0 0
(0) (1) (0)
“Cell lines were tested in the presence of 10-fold excess cold K562. “The 
percentage of lysis after blocking with a 1:150 dilution of W6/32 is shown in 
brackets.
synthesis, RNA from the cell lines was treated with DNAase I 
(Gibeo BRL, Breda, The Netherlands) for 30 min at 37°C followed 
by phenol extraction and precipitation. RNA isolations from the 
post-mortem tissues yielded such small amounts of RNA that we 
did not perform DNAase treatment. For cDNA synthesis, 2 jig of 
total RNA was reverse transcribed in first-strand buffer using 200 
U of M-MLV-RT (Gibco BRL) in the presence of 40 pmol of oligo- 
dT(18), 10 mM of each nucleotide, 200 nmol of DTT and 20 U of 
RNasin (Gibco BRL) in a volume of 20 (Ltl. After 1 h at 42°C, 
80 |il of sterile water was added (Van den Eynde et al,
The integrity of the cDNA was assessed by PCR for ß-actin.
PCR analysis
PCR was performed with 2.5 |il of the cDNA in 1 x PCR buffer, 
2 mM magnesium chloride, dNTP (10 mM each), 10 pmol of 
both primers, 0.05% W l, 0.5 U of Taq (Gibco BRL) in a volume 
of 25 (j.1. The PCR primers and programmes used were: ß-actin, 
sense 5'-GGCATCGTGATGGACTCCG-3', antisense 5'-GCTG- 
GAAGGTGGACAGCGA-3', 5 min at 94°C ( 1 min at 94°C, 
2 min at 68°C, 2 min at 72°C), 30x, 15 min at 72°C (Guilloux 
et al, 1996). GplOO, sense 5'-TATTGAAAGTGCCGAGATCC-3', 
antisense 5'-TGCAAGGACCACAGCCATC-3', 5 min at 94°C
( 1 min at 94°C, 1 min at 60°C, 1 min :), 35x, 15 min at 72°C
(Adenia et at, 1 . Tyrosinase, sense 5'-TTGGCAGATTGTCT-
GTAGCC-3', antisense 5'-AGGCATTÖTGCATGCTGCTT-3', 
5 min al 94°C ( 1 min at 94°C, 1 min at 60°C, 1 min at 72°C), 
30 X, 15 min at 72°C (Smith et al, 1991). MART-l/MelanA, sense
5 '-CTG ACCCTAC A AGATGCC 3-3', antisense 5'-ATCA-
TGCATTGCAACATTTATTGATGGAG-3', 5 min at 94°C (1 min
at 94°C, 2 min al 63°C, 2 min at 72°C) 35 x, 15 min at 72°C. 
RAGE-1, sense 5'-GTGTCTCCTTCGTCTCTACTA-3', antisense 
5'-GAGGTATTCCTGATCCTG-3', 5 min at 94°C (1 min at 
94°C, 2 min at 56°C, 3 min at 72°C), 33 x, 15 min at 72°C 
(Gaugler et al, 1996). The expected sizes of the PCR products 
were: ß-actin, 612 bp; gplOO, 360 bp; tyrosinase, 284 bp; MART- 
l/MelanA, 603 bp; RAGE-1, 239 bp. A total of 15 |Lil of the PCR
products was run on 2% agarose gels stained with ethidium 
bromide. For semi-quantitative analysis 0.2 j_tl of [32P]-dCTP was 
added to the PCR mixture. For both gplOO and ß-actin we 
observed that amplification was linear at 25 and 21 cycles respec­
tively. After amplification, 10 (al of the radioactive PCR products 
was separated on 6% acrylamide gels and the intensities of the 
PCR products were analysed using a Phosphor-Imager (Molecular 
Dynamics, Sunnyvale, CA, USA).
Cell lines Normal tissues
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gp100
Mart-1/MelanA
RAGE-1
Tyrosinase
[j-actin
Figure 1 RT-PCR analysis of tumour-associated antigens. RT-PCR products of gpl 00, MART-1, RAGE-1, tyrosinase and |i-actin transcripts in tumour cell lines 
(left) and in normal tissues (right) were detected by ethidium bromide-stained 2% agarose gels. The samples were loaded as indicated on the top of the figure. 
At the left, the positions of the kb marker are indicated. The upper band in the gp100 PCR indicated in the figure with an asterisk is the result of amplification of 
genomic DNA
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Figure 3 Levels of gp100 expression in Mel 624, MCF-7 and JY cell lines. 
cDNA as indicated in the figure was used in various dilutions in a radioactive 
RT-PCR. The PCR products of ß-actin (top) or gp100 (lower) were separated 
on acrylamide gels and quantified by phosphor-imaging
Figure 2 Expression of gp100 protein In RCC cell lines as determined by 
Western blotting. Lartes 1-4, RCC cell lines as indicated in the figure; lane 5, 
COS-7 cells; lanes 6 and 7, melanoma cell lines as indicated. The numbers 
on the left indicate the positions of the protein molecular weight marker
has been to be specific for cells of the
Western blotting
Cell lysates were prepared according to Vennegoor et al (1988).
An aliquot of protein was loaded (20 jug per lane) on a 10% SDS-
i
PAGE. Human gplOO was detected by polyclonal rabbit antiserum 
AZN-LAM, which was raised against the C-terminal 16-mer 
peptide of human gplOO protein, and which was chemically 
coupled to KLH (Pierce, Rockford, IL, USA). The serum was used 
in a 1:3000 dilution for Western blotting. For immunodetection, 
goat anti-rabbit-peroxidase (Zymed, San Francisco, CA, USA) and 
ECL (Amersham, Buckinghamshire, UK) were used (MWJS 
manuscript in preparation).
Cytotoxicity assay
Cytotoxicity towards the cell lines was performed as described 
previously (Bakker et al, 1995). The target cells were pretreated 
with 50 U m l1 y-IFN for 48 h before testing. Antibody blocking of
was performed by incubation of the chromium- 
labelled target cells with W6/32 ascites in 1:100 dilution at 20°C 
for 30 min. The final concentration of W6/32 was 1:150.
melanocyte lineage. This was based on immunohistochemical 
analysis and Northern analysis but not on results from RT-PCR 
(Vennegoor et al, 1988; Kawakami et al, 1994). To investigate 
further the presence of gp 100 transcripts in non-melanocytic cells, 
we analysed different normal tissues. Figure 1 shows that 9 out of 
11 of the tested samples were positive for gplOO, including seven 
from fresh normal tissues and two from EBV-transformed B-cell 
lines. The upper band that was sometimes observed in the fresh 
normal tissues is derived from genomic DNA contamination. In 
the gplOO sequence a small intron of 102 nt is present between the 
primers that were used for the gplOO PCR. After DNAase 
treatment of RNA before cDNA synthesis, the upper band is not 
amplified. To confirm that the amplified product was derived from 
gplOO transcripts, we cloned the PCR product and sequenced ten 
independent clones. These all represented the gplOO cDNA 
sequence (data not shown). In addition, another primer set specific 
for the 5' end of the gplOO mRNA yielded PCR products of the 
expected size (not shown). In agreement with the literature, no 
gp 100-specific hybridization could be detected by Northern blot­
ting (not shown) (Kawakami et al, 1994).
No gp100 protein was detected by Western blotting
Next, we analysed whether gplOO protein could be detected by 
Western blotting (Figure 2). In Mel 603 and MZ-7.4-meI, positive 
for gplOO by RT-PCR, gplOO protein was clearly detected by the 
AZN-LAM antiserum. In the RCC cell lines Camejo, LE-9104- 
RCC, SK-RC-7, LE-921 l-RCC, which were all positive using RT- 
PCR (not shown), no gplOO protein was detected. COS-7 cells 
were negative for gplOO by RT-PCR and Western blotting.
RESU LTS
gp100 but not MART-1/MelanA or tyrosinase transcripts 
can be detected by RT-PCR in tumour cell lines and 
normal tissues
To assess tumour antigen expression by a panel of tumour cell 
lines including cell lines of non-melanocytic origin, we applied 
RT-PCR for the currently known tumour-specific and melanocyte Although we did not detect gplOO protein by Western blotting in 
lineage-specific antigens that may serve as targets for tumour- the RCC cell lines that were all found to be positive by RT-PCR, 
specific cytotoxic T cells (CTL). Unexpectedly, we found gplOO antigenic processing of a very small amount of gplOO protein 
transcripts in cell lines of non-melanocytic origin, including 24/24 might still lead to MHC class I-mediated presentation of gplOO 
renal cell carcinoma cell lines, 8/8 ovarian carcinoma cell lines and peptides. As CTL recognition requires only a few antigenic
Cytotoxicity
6/6 breast carcinoma cell lines. In Figure 1, the gp 100-specific 
PCR products of a representative selection of these different cell 
lines are shown. In contrast, no tyrosinase or MART-l/MelanA 
transcripts were detected, except in cells of melanocytic origin. 
The RAGE-1 cDNA, which was recently cloned from a renal cell 
carcinoma cell line, was detected in RCC cell line MZ-1851-RCC 
and in fresh retina (Figure 1) (Gaugler et al, 1996).
complexes on the cell surface, we tested a number of HLA- 
A*0201-positive, gp 100-positive RCC cell lines for lysis using the 
gp 100-specific TIL 1200 cytotoxic T-cell line (Bakker et al, 1995). 
None of the HLA-A*0201-positive, gp 100-positive RCC cell lines 
was lysed, whereas the control melanoma cell line Mel 624 was 
readily lysed, suggesting that the level of expression of gplOO 
occurs at an immunologically irrelevant level (Table 1 ).
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Low expression of gplOO transcripts in RCC
Although gplOO transcripts can he detected by RT-PCR in various 
tissues, the gpl(K) protein is apparently not delected by cytotoxic T 
cells. To investigate whether this is caused by low transcription 
levels, we used semiquanlitalive PCR to compare the levels of 
expression in the various cell lines with that of Mel 624. 
Radioactive PCR for either ß-actin or gp 100 was performed using 
21 and 25 cycles of amplification respectively, and the products 
were run on acrylamide gels and quantified by phosphor-imaging. 
The- ß-actin signals in Mel 624 and MCF-7 were similar, whereas 
the signal in JY cells was higher at the different cDNA dilutions 
(Figure 3). The gplOO signal, however, could readily be detected
in the melanoma cell line even after a 1:10 '-fold , but 1:5
for gplOO expression within tumour material should be performed 
by antibody staining. Our experiments suggest that lysis by gplOO- 
specifie T cells only correlates with expression of gplOO at the 
protein level but not with RT-PCR expression data. Alternatively, a 
threshold value of gplOO expression, at which CTL recognition 
still occurs, should be determined by semiquantitative PCR. A 
similar situation probably exists for the melanoma-specific antigen 
/V-acetylglucosaminyl-transferase V, which could be detected by 
RT-PCR but not by CTL, when the antigen was expressed at levels 
lower than 8% of the reference (Guilloux et al, 1996). Our data 
indicate that a tightly controlled, semiquantitative PCR protocol 
should be developed in which gplOO is only detected when 
expressed at biologically révélant levels.
dilutions of the cDNA of MCF-7 and JY cells yielded barely 
detectable gp l()()-specific PCR products. ACKNOWLEDGEMENTS
We acknowledge Dr V Brichî
DISCUSSION
In this study we show that the melanocyte lineage-specific antigen 
gplOO can be detected by RT-PCR in tumour cell lines originating 
from tissues other than those of the melanocytic lineage. For the 
gp 100 PCR, we used 35 cycles of amplification, which is similar 
to the number of cycles that is used for the MART-l/MelanA and 
RAGE-1 PCR - 35 and 33 respectively. GplOO PCR products 
could even be detected with 30 cycles (not shown), indicating that 
gplOO transcripts are relatively easily amplified from cell lines of 
non-melanocytic origin. In contrast, transcription of MART- 
l/MelanA or tyrosinase is strictly confined to melanocyte lineage- 
specific cells. In normal tissues, including oesophagus, heart, 
kidney, liver, lymph node, ovary, retina and thyroid, gplOO was 
also detected by RT-PCR. Interestingly, we have not succeeded in 
detecting gp 100 in blood from healthy donors. Using a nested PCR 
approach, however, Mersey el al. (personal communication) were 
able to detect gplOO in the blood of healthy donors.
In contrast to other antigens that were identified by expression 
cloning with specific T cells, the gplOO antigen was first identified 
by antibody reactivity (Vennegoor el ai, 1988; Adema el al, 1994). 
Staining with MAbs NKl/beteb or HMB-45 could only be detected 
in cells of the melanocytic lineage. After cloning of the gplOO 
DNA. the tissue-specific distribution was confirmed by Northern 
analysis (Kawakami el al, 1994). The gplOO protein is a trans­
membrane protein that localizes primarily on the inside of preme- 
lanosomal vesicles. The function of the protein is unknown at 
present. Using RT-PCR, we show that there is a low level of tran­
scription of gplOO in virtually every cell type. Similar findings 
were published by Chelly et al (1989), who showed that various 
other tissue specific genes could be detected by RT-PCR in various 
tissues. They suggested that modification of the chromatin struc­
ture during DNA replication allowed ubiquitous transcription 
factors to bind to their cognate DNA elements, resulting in a low 
level of transcription. The level of gplOO protein expressed, 
however, is undetectable in these cell types. From these findings 
we conclude that gplOO can still be considered as a marker for 
cells of melanocytic lineage.
Research, Brussels, Belgium) for providing MART-l/MelanA- 
specific primer sequences. We thank Ms AK Marijnissen and 
Ms D van Oorschot (Leiden University) for providing breast and 
ovarian carcinoma material. This work was supported by a grant 
from the Dutch Cancer Society (RUL95-1054).
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